ArticlePharmaceutical research2021
Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.
Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- AutoPK: Leveraging LLMs and a Hybrid Similarity Metric for Advanced Retrieval of Pharmacokinetic Data from Complex Tables and Documents.International Conference on Tools with Artificial Intelligence : [proceedings]. International Conference on Tools for Artificial Intelligence · 2025Article
- Indirect Modeling of Post-Prandial Intestinal Lymphatic Uptake of Halofantrine Using PBPK Approaches: Limitations and Implications.Pharmaceutics · 2025Article
- The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology.Pharmaceutical research · 2025Review
- Innovative applications and future perspectives of chromatography-mass spectrometry in drug research.Frontiers in pharmacology · 2025Review
- FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes.Pharmaceutics · 2024Article
- Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence.Pharmaceutical research · 2024Article
- Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption.Pharmaceutical research · 2023Article
- The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics.Journal of pharmacokinetics and pharmacodynamics · 2023Article
- An Analytical Solution for Saturable Absorption in Pharmacokinetics Models.Pharmaceutical research · 2023Article
- Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept.Pharmaceutical research · 2023Article
- Establishment of a multicomponent quality control method and the transfer characteristics of five markers from Qidongning Formula to rat tissues by HPLC-QQQ-MS/MS.Frontiers in pharmacology · 2023Article
- Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models.Pharmaceutical research · 2022Article
- Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.Pharmaceutical research · 2021Article
- Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts.Pharmaceutical research · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the application of the parameters of the physiologically based finite time pharmacokinetic (PBFTPK) models subdivided in first-order (PBFTPK)
methodsSimulated concentration time data were generated from the Bateman equation and compared with data generated from the (PBFTPK)
resultsThe simulated data of the (PBFTPK)
conclusionThe (PBFTPK)
Indexed as
Identifiers
34341958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.